13 completed, 3 terminated, 1 active not recruiting. 10 Phase 2, 6 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 7, Terminated 2, Active not recruiting 1 |
| Phase 1 | 6 | Completed 6 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow cenicriviroc: new trials by email Literature Review of cenicriviroc trials Research Report on cenicriviroc
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immune Modulators for Treating COVID-19 Infliximab, Abatacept, Remdesivir - Covid19 | Phase 3 | Completed | Daniel Benjamin | 1971 | 2020-10-15 | 2023-09-25 |
| Charité Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients Cenicriviroc (CVC), Placebo - Covid19 | Phase 2 | Terminated | Charite University, Berlin, Germany | 45 | 2020-08-25 | 2022-03-29 |
| I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients Remdesivir, Imatinib Mesylate, Dexamethasone - COVID-19 | Phase 2 | Active not recruiting | QuantumLeap Healthcare Collaborative | 1500 | 2020-07-31 | 2026-03-16 |
| Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis Tropifexor (LJN452), Cenicriviroc (CVC) - Non-alcoholic Steatohepatitis (NASH) | Phase 2 | Completed | Novartis Pharmaceuticals | 193 | 2018-09-11 | 2022-04-29 |
| Impact of Severe Hepatic Impairment on Pharmacokinetics of Cenicriviroc and Its Metabolites Cenicriviroc - Hepatic Impairment | Phase 1 | Completed | Allergan | 16 | 2017-06-06 | 2018-01-11 |
| AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH) Placebo, Cenicriviroc - Nonalcoholic Steatohepatitis | Phase 3 | Terminated | Tobira Therapeutics, Inc. | 1778 | 2017-04-05 | 2022-03-10 |
| Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis Cenicriviroc - Nonalcoholic Steatohepatitis, Liver Cirrhosis | Phase 2 | Terminated | Tobira Therapeutics, Inc. | 167 | 2017-02-14 | 2022-02-02 |
| PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Participants With Primary Sclerosing Cholangitis Cenicriviroc 150 mg - Primary Sclerosing Cholangitis | Phase 2 | Completed | Tobira Therapeutics, Inc. | 24 | 2016-03-14 | 2018-10-01 |
| Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination Cenicriviroc, Omeprazole, Famotidine - Healthy | Phase 1 | Completed | Tobira Therapeutics, Inc. | 48 | 2016-01-31 | 2017-11-24 |
| ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or Type 2 Diabetes Mellitus (T2DM) and Suspected NAFLD Cenicriviroc 150 mg, Placebo - Prediabetic State, Non-alcoholic Fatty Liver Disease | Phase 2 | Completed | Tobira Therapeutics, Inc. | 45 | 2015-07-17 | 2019-10-11 |
| Pharmacokinetic and Safety Study of Cenicriviroc and Pioglitazone, When Dosed Alone or in Combination Cenicriviroc, Pioglitazone - Healthy | Phase 1 | Completed | Tobira Therapeutics, Inc. | 20 | 2014-12-01 | 2015-05-12 |
| Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis Cenicriviroc, Placebo - Nonalcoholic Steatohepatitis | Phase 2 | Completed | Tobira Therapeutics, Inc. | 289 | 2014-09-18 | 2019-05-10 |
| Effect of Cenicriviroc on HIV Neurocognitive Impairment cenicriviroc - AIDS Dementia Complex, HIV-1-Associated Cognitive Motor Complex | Phase 2 | Completed | University of Hawaii | 20 | 2014-04-01 | 2020-08-20 |
| Phase 1 Study of Multiple-Dose Pharmacokinetics of Cenicriviroc in Subjects With Mild and Moderate Hepatic Impairment Cenicriviroc in mild liver impaired, Cenicriviroc in moderate liver impaired - Liver Insufficiency | Phase 1 | Completed | Tobira Therapeutics, Inc. | 31 | 2014-03-01 | 2014-08-21 |
| Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of Midazolam Cenicriviroc, Dolutegravir, Midazolam - HIV-infection/AIDS | Phase 1 | Completed | Tobira Therapeutics, Inc. | 20 | 2013-03-01 | 2014-04-09 |
| Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus Cenicriviroc 100 mg, Cenicriviroc 200 mg + Truvada, Sustiva + Truvada - HIV-1 Infection | Phase 2 | Completed | Tobira Therapeutics, Inc. | 143 | 2011-06-01 | 2013-07-10 |
| A Proof of Concept Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients TBR-652, TBR-652 Matching Placebo, TBR-652 50 mg - HIV-1 Infection | Phase 1 / Phase 2 | Completed | Tobira Therapeutics, Inc. | 52 | 2009-02-01 | 2013-07-10 |
Non-alcoholic Fatty Liver Disease (5) · COVID-19 (3) · Acquired Immunodeficiency Syndrome (2) · Hepatic Insufficiency (2) · Liver Cirrhosis (2) · AIDS Dementia Complex (1) · Cholangitis, Sclerosing (1) · Diabetes Mellitus, Type 2 (1) · Disease (1) · Fatty Liver (1) · Prediabetic State (1) · Respiratory Distress Syndrome (1) · Respiratory Insufficiency (1)
Tobira Therapeutics, Inc. (11) · Allergan (1) · Charite University, Berlin, Germany (1) · Daniel Benjamin (1) · Novartis Pharmaceuticals (1) · QuantumLeap Healthcare Collaborative (1) · University of Hawaii (1)
United States (15) · Germany (5) · Belgium (4) · France (4) · Italy (4) · Puerto Rico (4) · Spain (4) · United Kingdom (4) · Australia (3) · Canada (3) · Hong Kong (3) · Poland (3) · Argentina (2) · Brazil (2) · Israel (2)
Eric Lefebvre, MD (2) · Audrey Martinez, MD (1) · Bill Powderly, MD (1) · Cecilia Shikuma, MD (1) · Daniel K Benjamin, MD, PhD (1) · Derek W Russell, MD (1) · Eduardo B Martins (1) · Frank Tacke, Prof. Dr.med. (1) · Gerardo Rodriguez (1) · J.P. Nicandro (1) · Kathleen D Liu, MD (1) · Kenneth C Lasseter, MD (1) · Laura Esserman, MD (1) · Star Seyedkazemi, PharmD (1)
PMID 33666272, PMID 34473343, PMID 21317794, PMID 21486960, PMID 23875707, PMID 26636929, PMID 26944023, PMID 27347680, PMID 30239650, PMID 31731005, PMID 31943293, PMID 33681680, PMID 34454994, PMID 34951993, PMID 36172138, PMID 36203544, PMID 36883141, PMID 37061109, PMID 37428480, PMID 38662372, PMID 39592213, PMID 39610848, PMID 40462830, PMID 42799508
2016 (3), 2017 (1)